<!DOCTYPE drug_guide PUBLIC "-//ES//DTD drug_guide DTD version 3.1//EN//XML" "Y:\WWW1\tools\Drugs\3_1_drug.dtd">
<drug_guide isbn="9780323448260">
	<alpha letter="q">
		<monograph id="1" status="active">
			<mono_name>QUEtiapine (Rx)</mono_name>
			<info>
				<pronunciation>(kwe-tie′a-peen)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x221">Seroquel</tradename>
					<tradename id="tnidelem4x220">Seroquel XR</tradename>
				</tradenames>
				<class type="func"> Antipsychotic, atypical</class>
				<class type="chem"> Dibenzothiazepine</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="actions" id="sidelem4x32">
				<sec_title>Action:</sec_title>
				<para>Functions as an antagonist at multiple neurotransmitter receptors in the brain, including 5HT<emphasis style="inf">1A</emphasis>, 5HT<emphasis style="inf">2</emphasis>, dopamine D<emphasis style="inf">1</emphasis>, D<emphasis style="inf">2</emphasis>, H<emphasis style="inf">1</emphasis>, and adrenergic α<emphasis style="inf">1</emphasis>, α<emphasis style="inf">2</emphasis> receptors</para>
			</section>
			<section type="uses" id="sidelem4x58">
				<sec_title>Uses:</sec_title>
				<para>Bipolar disorder, bipolar I disorder, depression, mania, schizophrenia</para>
				<section type="none" id="sidelem4x63">
					<section type="none" id="sidelem4x64">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Agitation, dementia, OCD, acute psychosis</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x69">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, breastfeeding</para>
				<section type="none" id="sidelem4x74">
					<section type="none" id="sidelem4x75">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), geriatric patients, hepatic/cardiac disease, breast cancer, long-term use, seizures, QT prolongation, brain tumor, hematologic disease, torsades de pointes, cataracts, dehydration, abrupt discontinuation</para>
						<para>
							<bbw>Children, suicidal ideation, increased mortality in elderly patients with dementia-related psychosis</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x90">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x93">
					<section type="none" id="sidelem4x94">
						<sec_title>Bipolar I disorder</sec_title>
						<section type="none" id="sidelem4x102">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x102">
									<item>
										<label>•</label>
										<para> (monotherapy or adjunct to lithium, divalproex), (not at increased risk for hypotension) 50 mg bid on day 1, 100 mg on day 2 in 2 divided doses as tolerated to 400 mg/day on day 4, range 400-800 mg/day; ext rel give in evening 300 mg daily day 1, then 600 mg daily day 2, then adjusted as tolerated</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x109">
							<label>•</label>
							<sec_title>Geriatric, debilitated, or at risk for hypotension<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x109">
									<item>
										<label>•</label>
										<para> 25 mg bid, titrate upward slowly; ext rel 50 mg in evening, max 800 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x116">
							<label>•</label>
							<sec_title>Child ≥10 yr/adolescents<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x116">
									<item>
										<label>•</label>
										<para> 25 mg bid day 1, 50 mg bid day 2, 100 mg bid day 3, 150 mg bid day 4, 200 mg bid beginning day 5 dose adjusted, max 600 mg/day; ext rel 50 mg day 1, 100 mg day 2, 200 mg day 3, 300 mg day 4, 400 mg day 5, give in evening</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x120">
						<sec_title>Schizophrenia</sec_title>
						<section type="none" id="sidelem4x128">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x128">
									<item>
										<label>•</label>
										<para> (not at risk for hypotension) 25 mg bid on day 1, increase by 25-50 mg divided 2 to 3× on day 2 and day 3 to a target of 300-400 mg/day in divided doses by day 4, further dosage adjustment can be made in 25-50 mg bid increments, max 800 mg/day; (XR) 300 mg/day in <emphasis style="smallcaps">pm</emphasis>, range 400-800 mg/day, max 800 mg/day</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x138">
							<label>•</label>
							<sec_title>Adolescents 13-17 yr<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x138">
									<item>
										<label>•</label>
										<para> 25 mg bid on day 1, 50 mg bid on day 2, 100 mg bid on day 3, 150 mg bid on day 4, 200 mg on day 5; ext rel 50 mg on day 1, then 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, 400 mg on day 5</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x145">
							<label>•</label>
							<sec_title>Geriatric<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x145">
									<item>
										<label>•</label>
										<para> 50 mg/day may increase in 50 mg/day increments</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x149">
						<sec_title>Depressive disorder (inadequate response to antidepressants alone)</sec_title>
						<section type="none" id="sidelem4x157">
							<label>•</label>
							<sec_title>Adult<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x157">
									<item>
										<label>•</label>
										<para> 50 mg/day in <emphasis style="smallcaps">pm</emphasis> on days 1, 2; on day 3, give 150 mg in <emphasis style="smallcaps">pm</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x169">
							<label>•</label>
							<sec_title>Geriatric, debilitated or at risk for hypotension<route> PO EXT REL</route></sec_title>
							<para>
								<list id="lidelem4x169">
									<item>
										<label>•</label>
										<para> 50 mg on day 1 and 2, may increase by 50 mg/day based on response</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x173">
						<sec_title>Obsessive compulsive disorder (unlabeled)</sec_title>
						<section type="none" id="sidelem4x181">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x181">
									<item>
										<label>•</label>
										<para> 50 mg daily, increase on response, continue for 1-2 yr before tapering by 10-25% q1-2mo</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x185">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 25, 50, 100, 200, 300, 400 mg; ext rel tab 50, 150, 200, 300, 400 mg</para>
					</section>
					<section type="none" id="sidelem4x190">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x195">
								<item>
									<label>•</label>
									<para>Reduced dose to geriatric patients</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x200">
								<item>
									<label>•</label>
									<para>Avoid use of CNS depressants</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x205">
								<item>
									<label>•</label>
									<para>Store in tight, light-resistant container</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x213">
							<label>•</label>
							<sec_title>Immediate release</sec_title>
							<para>
								<list id="lidelem4x213">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Immediate release:</emphasis> without regard to meals</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x220">
							<label>•</label>
							<sec_title>Ext rel</sec_title>
							<para>
								<list id="lidelem4x220">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Ext rel:</emphasis> without food or with light meal ≤300 calories; swallow whole; do not split, crush, chew; can switch from immediate release to extended release by giving total daily dose daily</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x226">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x229">
					<section type="none" id="sidelem4x230">
						<sec_title>CNS:</sec_title>
						<para> EPS, pseudoparkinsonism, akathisia, dystonia, tardive dyskinesia; <emphasis style="italic">drowsiness,</emphasis> insomnia, agitation, anxiety, <emphasis style="italic">headache,</emphasis><emphasis style="bold">seizures, neuroleptic malignant syndrome,</emphasis><emphasis style="italic">dizziness,</emphasis> dystonia, restless legs</para>
					</section>
					<section type="none" id="sidelem4x245">
						<sec_title>CV:</sec_title>
						<para> Orthostatic hypotension, <emphasis style="bold">tachycardia, QT prolongation,</emphasis> CV disease, Parkinson’s disease, cardiomyopathy, myocarditis</para>
					</section>
					<section type="none" id="sidelem4x253">
						<sec_title>ENDO:</sec_title>
						<para> SIADH, hyperglycemia</para>
					</section>
					<section type="none" id="sidelem4x258">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea, anorexia, constipation,</emphasis> abdominal pain, dry mouth</para>
					</section>
					<section type="none" id="sidelem4x266">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Leukopenia, agranulocytosis</emphasis></para>
					</section>
					<section type="none" id="sidelem4x273">
						<sec_title>INTEG:</sec_title>
						<para> Rash</para>
					</section>
					<section type="none" id="sidelem4x278">
						<sec_title>META:</sec_title>
						<para> Hyponatremia</para>
					</section>
					<section type="none" id="sidelem4x283">
						<sec_title>MISC:</sec_title>
						<para> Asthenia, back pain, fever, ear pain</para>
					</section>
					<section type="none" id="sidelem4x288">
						<sec_title>MS: </sec_title>
						<para>
							<emphasis alert="lifethreat">Rhabdomyolysis</emphasis>
						</para>
					</section>
					<section type="none" id="sidelem4x294">
						<sec_title>RESP:</sec_title>
						<para> Rhinitis</para>
					</section>
					<section type="none" id="sidelem4x299">
						<sec_title>SYST:</sec_title>
						<para> <emphasis style="bold">Stevens-Johnson syndrome, anaphylaxis</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x306">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Extensively metabolized by liver, half-life ≥6 hr, peak 11/2 hr, ext rel 6 hr, inhibits P450 CYP3A4 enzyme system, 83% protein binding, excretion: &lt;1% unchanged urine</para>
			</section>
			<section type="interactions" id="sidelem4x311">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis alert="nurse">Increase: QT prolongation—class IA/III antidysrhythmics, some phenothiazines, β-agonists, local anesthetics, tricyclics, haloperidol, methadone, chloroquine, clarithromycin, droperidol, erythromycin, pentamidine</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> CNS depression—alcohol, opioid analgesics, sedative/hypnotics, antihistamines</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—alcohol, antihypertensives</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> QUEtiapine clearance, decrease QUEtiapine effect—phenytoin, thioridazine, barbiturates, glucocorticoids, carBAMazepine, rifampin</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> neurotoxicity—lithium</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> QUEtiapine action—fluconazole, itraconazole, ketoconazole (CYP3A4 inhibitors)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of erythromycin</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> QUEtiapine clearance—cimetidine</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> effects of DOPamine agonists, levodopa, LORazepam</para>
				<section type="none" id="sidelem4x351">
					<section type="none" id="sidelem4x352">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> cholesterol, triglycerides, LFTs, glucose</para>
						<para>
							<emphasis style="bold">Decrease:</emphasis> thyroid tests, WBC</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x363">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x366">
					<section type="none" id="sidelem4x367">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x373">
								<item>
									<para>
										<emphasis alert="nurse">CV status: QT prolongation, tachycardia, orthostatic B/P</emphasis>
<bbw>Mental status before initial administration, AIMS assessment; affect, orientation, LOC, reflexes, gait, coordination, sleep pattern disturbances; suicidal thoughts/behaviors (child/young adult); dementia (geriatric patients)</bbw>

<bbw>Not to be used in child &lt;10 yr (imm rel) or &lt;18 yr (ext rel)</bbw>

<bbw>
											<emphasis alert="lifethreat">Suicide:</emphasis> restrict amount of product given; usually suicidal thoughts/behaviors occur early during treatment and among children/adolescents/young adults</bbw>
</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x407">
								<item>
									<label>•</label>
									<para>Baseline blood glucose, LFTs, neurologic function, ophthalmologic exam, weight, monitor glucose often in diabetes mellitus, thyroid function tests, serum electrolytes/creatinine/lipid profile/prolactin</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x412">
								<item>
									<label>•</label>
									<para>B/P standing, lying; pulse, respirations; determine q4hr during initial treatment; establish baseline before starting treatment; report drops of 30 mm Hg; watch for ECG changes</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x417">
								<item>
									<label>•</label>
									<para>Dizziness, faintness, palpitations, tachycardia on rising</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x425">
							<label>•</label>
							<sec_title>EPS</sec_title>
							<para>
								<list id="lidelem4x425">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">EPS:</emphasis> including akathisia (inability to sit still, no pattern to movements), tardive dyskinesia (bizarre movements of jaw, mouth, tongue, extremities), pseudoparkinsonism (rigidity, tremors, pill rolling, shuffling gait)</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x433">
								<item>
									<para>
										<emphasis alert="nurse">Neuroleptic malignant syndrome: hyperthermia, increased CPK, altered mental status, muscle rigidity, seizures, tachycardia, diaphoresis, hypo/hypertension, fatigue; notify prescriber immediately if symptoms occur</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x438">
								<item>
									<label>•</label>
									<para>Constipation, urinary retention daily; if these occur, increase bulk, water in diet</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x443">
								<item>
									<label>•</label>
									<para>Supervised ambulation until patient stabilized on medication; do not involve patient in strenuous exercise program because fainting possible; patient should not stand still for long period of time</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x448">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x452">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in emotional excitement, hallucinations, delusions, paranoia; reorganization of patterns of thought, speech</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x458">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x463">
								<item>
									<label>•</label>
									<para>Not to become overheated, drink plenty of fluids</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x468">
								<item>
									<label>•</label>
									<para>To rise slowly to prevent orthostatic hypotension</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x473">
								<item>
									<label>•</label>
									<para>To take medication only as prescribed; not to crush, chew ext rel product; not to use with alcohol; to take regular tabs without regard to food, ext rel without food, not to use other products unless approved by prescriber; not to stop abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x478">
								<item>
									<label>•</label>
									<para>That follow-up is necessary, including LFTs, blood glucose, neurologic, cholesterol profile, weight</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x483">
								<item>
									<label>•</label>
									<para>If drowsiness occurs, to avoid hazardous activities such as driving; not to stand quickly, may be worse during first few days of dose change</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x488">
								<item>
									<label>•</label>
									<para>To avoid use of OTC meds unless directed by prescriber</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x496">
							<label>•</label>
							<sec_title>
								<route>To notify prescriber if pregnancy planned, suspected; not to breastfeed</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x502">
							<para>
								<list id="lidelem4x502">
									<item>
										<label>•</label>
										<para>To notify prescriber immediately of fever, difficulty breathing, fatigue, sore throat, rash, bleeding
<bbw>
												<emphasis alert="lifethreat">Suicide:</emphasis> Thoughts/behaviors, primarily among children/adolescents/young adults</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x515">
								<item>
									<label>•</label>
									<para>To have eye exam before treatment and q6mo, cataracts may occur</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="2" status="active">
			<mono_name>quinapril (Rx)</mono_name>
			<info>
				<pronunciation>(kwin′a-pril)</pronunciation>
				<tradenames>
					<tradename id="tnidelem4x5250">Accupril</tradename>
				</tradenames>
				<class type="func"> Antihypertensive</class>
				<class type="chem"> Angiotensin-converting enzyme (ACE) inhibitor</class>
				<class type="preg">Pregnancy category <preg cat="D">D</preg></class>
			</info>
			<section type="confusion" id="sidelem4x535">
				<para>
					<confusion>
						<tradename id="tnidelem4x5350">Accupril</tradename>
						<drug type="generic" refid="idelem4x5350">Aciphex</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x539">
				<sec_title>Action:</sec_title>
				<para>Selectively suppresses renin-angiotensin-aldosterone system; inhibits ACE, prevents conversion of angiotensin I to angiotensin II; results in dilation of arterial, venous vessels</para>
			</section>
			<section type="uses" id="sidelem4x544">
				<sec_title>Uses:</sec_title>
				<para>Hypertension, alone or in combination with thiazide diuretics; systolic CHF</para>
			</section>
			<section type="contra" id="sidelem4x549">
				<sec_title>Contraindications:</sec_title>
				<para>Children, hypersensitivity to ACE inhibitors, angioedema</para>
				<para>
					<bbw>Pregnancy (D)</bbw>
				</para>
				<section type="none" id="sidelem4x564">
					<section type="none" id="sidelem4x565">
						<sec_title>Precautions:</sec_title>
						<para> Breastfeeding, geriatric patients, impaired renal/hepatic function, dialysis patients, hypovolemia, blood dyscrasias, bilateral renal stenosis, cough, hyperkalemia, aortic stenosis, African descent</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x570">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x573">
					<section type="none" id="sidelem4x574">
						<sec_title>Hypertension</sec_title>
						<section type="none" id="sidelem4x582">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x582">
									<item>
										<label>•</label>
										<para> 10-20 mg/day initially, then 20-80 mg/day divided bid or daily (monotherapy); start at 5 mg/day (with diuretics), titrate ≥2 wk</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x589">
							<label>•</label>
							<sec_title>Geriatric<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x589">
									<item>
										<label>•</label>
										<para> 10 mg/day, titrate to desired response (monotherapy); start at 2.5 mg/day (with diuretics)</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x593">
						<sec_title>Congestive heart failure</sec_title>
						<section type="none" id="sidelem4x601">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x601">
									<item>
										<label>•</label>
										<para> 5 mg bid, may increase weekly until 20-40 mg/day in 2 divided doses</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x605">
						<sec_title>Renal dose</sec_title>
						<section type="none" id="sidelem4x613">
							<label>•</label>
							<sec_title>Adult<route> PO CCr 61-89 ml/min 10 mg daily (hypertension), 5 mg bid (heart failure); CCr 30-60 ml/min, 5 mg/day initially; CCr 10-29 ml/min, 2.5 mg/day initially</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x616">
						<sec_title>Available forms:</sec_title>
						<para> Tabs 5, 10, 20, 40 mg</para>
					</section>
					<section type="none" id="sidelem4x621">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x625">
								<item>
									<label>•</label>
									<para>Tabs may be crushed if necessary</para>
								</item>
								<item>
									<label>•</label>
									<para>Store in airtight container at room temperature</para>
								</item>
								<item>
									<label>•</label>
									<para>Do not use with high-fat meal, decreases absorption</para>
								</item>
							</list>
						</para>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x641">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x644">
					<section type="none" id="sidelem4x645">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness, fatigue,</emphasis> somnolence, depression, malaise, nervousness, vertigo, syncope</para>
					</section>
					<section type="none" id="sidelem4x653">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="italic">Hypotension,</emphasis> postural hypotension, syncope, palpitations, <emphasis style="italic">angina pectoris,</emphasis><emphasis style="bold">MI, tachycardia,</emphasis> vasodilation, chest pain</para>
					</section>
					<section type="none" id="sidelem4x666">
						<sec_title>GI:</sec_title>
						<para> <emphasis style="italic">Nausea,</emphasis> diarrhea, constipation, <emphasis style="italic">vomiting,</emphasis> gastritis, <emphasis style="bold">GI hemorrhage,</emphasis> dry mouth</para>
					</section>
					<section type="none" id="sidelem4x680">
						<sec_title>GU:</sec_title>
						<para> Increased BUN, creatinine; decreased libido, impotence</para>
					</section>
					<section type="none" id="sidelem4x685">
						<sec_title>INTEG:</sec_title>
						<para> <emphasis style="bold">Angioedema,</emphasis> rash, sweating, photosensitivity, pruritus</para>
					</section>
					<section type="none" id="sidelem4x693">
						<sec_title>META:</sec_title>
						<para> Hyperkalemia</para>
					</section>
					<section type="none" id="sidelem4x698">
						<sec_title>MISC:</sec_title>
						<para> Back pain, amblyopia</para>
					</section>
					<section type="none" id="sidelem4x703">
						<sec_title>MS:</sec_title>
						<para> Myalgia</para>
					</section>
					<section type="none" id="sidelem4x708">
						<sec_title>RESP:</sec_title>
						<para> <emphasis style="italic">Cough,</emphasis> pharyngitis, dyspnea</para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x716">
				<sec_title>Pharmacokinetics</sec_title>
				<para>Bioavailability ≥60%, onset &lt;1 hr, peak 1-2 hr, duration 24 hr, protein binding 97%, half-life 2 hr, metabolized by liver (active metabolites quinaprilat), metabolites excreted in urine (60%)/feces (37%)</para>
			</section>
			<section type="interactions" id="sidelem4x721">
				<sec_title>Interactions</sec_title>
				<para>
					<emphasis style="bold">Increase:</emphasis> hyperkalemia—vasodilators, hydrALAZINE, prazosin, potassium-sparing diuretics, sympathomimetics, potassium supplements, ACE/angiotensin II receptor antagonists; aliskiren (diabetic patients)</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> hypotension—diuretics, other antihypertensives, ganglionic blockers, adrenergic blockers, phenothiazines, nitrates, acute alcohol ingestion</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> toxicity of lithium</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> absorption of tetracycline, quinolone antibiotics</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> hypotensive effect of quinapril—NSAIDs</para>
				<section type="none" id="sidelem4x744">
					<section type="none" id="sidelem4x745">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<list id="lidelem4x750">
								<item>
									<label>•</label>
									<para>Cough: capsaicin</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x758">
							<label>•</label>
							<sec_title>Decrease</sec_title>
							<para>
								<list id="lidelem4x758">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Decrease:</emphasis> antihypertensive effect—ma huang</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x762">
						<sec_title>Drug/Food</sec_title>
						<section type="none" id="sidelem4x770">
							<label>•</label>
							<sec_title>Hyperkalemia</sec_title>
							<para>
								<list id="lidelem4x770">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hyperkalemia:</emphasis> do not use with potassium-containing salt substitutes, read label carefully</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x774">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> potassium, creatinine, BUN, LFTs</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x781">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x784">
					<section type="none" id="sidelem4x785">
						<sec_title>Assess:</sec_title>
						<section type="none" id="sidelem4x791">
							<sec_title>Collagen-vascular disease<route> blood studies</route></sec_title>
							<para>
								<list id="lidelem4x791">
									<item>
										<para>
											<emphasis alert="nurse">Collagen-vascular disease: blood studies: neutrophils, decreased platelets; WBC with differential at baseline, periodically, q3mo; if neutrophils &lt;1000/mm</emphasis>
											<emphasis style="sup">
												<emphasis style="bold">3</emphasis>
											</emphasis>, <emphasis alert="nurse">discontinue treatment</emphasis></para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x805">
							<label>•</label>
							<sec_title>Hypertension</sec_title>
							<para>
								<list id="lidelem4x805">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">Hypertension:</emphasis> B/P, orthostatic hypotension, syncope, monitor B/P before giving and after 2 hr; African American patients are more resistant to antihypertension effect</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x809">
								<item>
									<label>•</label>
									<para>Renal studies: protein, BUN, creatinine; watch for increased levels; may indicate nephrotic syndrome</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x814">
								<item>
									<label>•</label>
									<para>Baselines of hepatic studies before therapy, periodically; increased LFTs; uric acid, glucose may be increased</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x819">
								<item>
									<label>•</label>
									<para>Potassium levels; hyperkalemia rare</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x827">
							<label>•</label>
							<sec_title>CHF</sec_title>
							<para>
								<list id="lidelem4x827">
									<item>
										<label>•</label>
										<para>
											<emphasis style="bold">CHF:</emphasis> edema in feet, legs daily; weight daily</para>
									</item>
								</list>
							</para>
						</section>
						<para>
							<list id="lidelem4x832">
								<item>
									<para>
										<emphasis alert="nurse">Allergic reactions: rash, fever, pruritus, urticaria, swelling of eyes/face/throat/neck, SOB, difficulty breathing; product should be discontinued; angioedema is more common in African American patients</emphasis>
<bbw>For pregnancy (D), 2nd/3rd trimester, if pregnancy is suspected, discontinue use</bbw>
</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x847">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x851">
								<item>
									<label>•</label>
									<para>Therapeutic response: decrease in B/P</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x857">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x862">
								<item>
									<label>•</label>
									<para>Not to discontinue product abruptly</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x867">
								<item>
									<label>•</label>
									<para>Not to use OTC products (cough, cold, allergy); not to use salt substitutes containing potassium unless directed by prescriber, avoid high-fat meal at same time as product</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x872">
								<item>
									<label>•</label>
									<para>To comply with dosage schedule, even if feeling better</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x877">
								<item>
									<label>•</label>
									<para>To rise slowly to sitting or standing position to minimize orthostatic hypotension, to report excessive perspiration, dehydration, vomiting, diarrhea; may lead to fall in B/P; maintain adequate hydration</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x882">
								<item>
									<label>•</label>
									<para>To notify prescriber of mouth sores, sore throat, fever, swelling of hands/feet, irregular heartbeat, chest pain, persistent dry cough</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x887">
								<item>
									<label>•</label>
									<para>That product may cause dizziness, fainting, lightheadedness; may occur during first few days of therapy</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x892">
								<item>
									<label>•</label>
									<para>That product may cause skin rash, impaired taste perception</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x900">
							<para>
								<list id="lidelem4x900">
									<item>
										<label>•</label>
										<para>How to take B/P, normal readings for age group
<bbw>
												<emphasis alert="lifethreat">Pregnancy:</emphasis> to report if pregnancy planned, suspected; pregnancy category (D) 2nd/3rd trimester; do not breastfeed</bbw>
</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
			</section>
		</monograph>
<monograph id="3" status="active" ha="yes">
			<mono_name> quiNIDine gluconate (Rx)</mono_name>
			<info>
				<pronunciation>(kwin′i-deen)</pronunciation>
			</info>
		</monograph>
<monograph id="4" status="active">
			<mono_name>quiNIDine sulfate (Rx)</mono_name>
			<info>
				<class type="func"> Antidysrhythmic (Class IA)</class>
				<class type="chem"> Quinine dextroisomer</class>
				<class type="preg">Pregnancy category <preg cat="C">C</preg></class>
			</info>
			<section type="confusion" id="sidelem4x936">
				<para>
					<confusion>
						<tradename id="tnidelem4x9360">quiNIDine</tradename>
						<drug type="generic" refid="idelem4x9360">quiNINE</drug>
					</confusion>
				</para>
			</section>
			<section type="actions" id="sidelem4x940">
				<sec_title>Action:</sec_title>
				<para>Prolongs duration of action potential and effective refractory period, thus decreasing myocardial excitability; anticholinergic properties</para>
			</section>
			<section type="uses" id="sidelem4x945">
				<sec_title>Uses:</sec_title>
				<para>Atrial fibrillation, PAT, ventricular tachycardia, atrial flutter, Wolff-Parkinson-White syndrome; PVST, malaria/IV quiNIDine gluconate</para>
				<section type="none" id="sidelem4x950">
					<section type="none" id="sidelem4x951">
						<sec_title>Unlabeled uses:</sec_title>
						<para> Singultus (hiccups)</para>
					</section>
				</section>
			</section>
			<section type="contra" id="sidelem4x956">
				<sec_title>Contraindications:</sec_title>
				<para>Hypersensitivity, idiosyncratic response, digoxin toxicity, blood dyscrasias, myasthenia gravis, AV block</para>
				<section type="none" id="sidelem4x961">
					<section type="none" id="sidelem4x962">
						<sec_title>Precautions:</sec_title>
						<para> Pregnancy (<preg cat="C">C</preg>), breastfeeding, children, geriatric patients, electrolyte imbalance, renal/hepatic disease, CHF, respiratory depression, bradycardia, hypotension, syncope</para>
						<para>
							<bbw>Cardiac arrhythmias, MI</bbw>
						</para>
					</section>
				</section>
			</section>
			<section type="doses" id="sidelem4x977">
				<sec_title>Dosage and routes</sec_title>
				<section type="none" id="sidelem4x980">
					<sec_title>QuiNIDine gluconate</sec_title>
					<section type="none" id="sidelem4x988">
						<label>•</label>
						<sec_title>Adult<route> PO</route></sec_title>
						<para>
							<list id="lidelem4x988">
								<item>
									<label>•</label>
									<para> (ext rel) 324-648 mg q8-12hr;  600 mg, then 400 mg q2hr;  give 16 mg/min</para>
								</item>
							</list>
						</para>
					</section>
					<para>Severe <emphasis style="italic">Plasmodium falciparum</emphasis></para>
					<section type="none" id="sidelem4x1002">
						<sec_title>Malaria</sec_title>
						<section type="none" id="sidelem4x1010">
							<label>•</label>
							<sec_title>Adult<route> IV</route></sec_title>
							<para>
								<list id="lidelem4x1010">
									<item>
										<label>•</label>
										<para> 10 mg/kg/dose over 1-2 hr, then IV Infusion of 0.02 mg/kg/min for ≥24 hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
				</section>
				<section type="none" id="sidelem4x1014">
					<sec_title>QuiNIDine sulfate</sec_title>
					<section type="none" id="sidelem4x1017">
						<sec_title>PVST/WPW/atrial fibrillation/flutter</sec_title>
						<section type="none" id="sidelem4x1025">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1025">
									<item>
										<label>•</label>
										<para> 200-300 mg q6-8hr × 5-8 doses; may increase daily until sinus rhythm restored; max 4 g/day given only after digitalization; maintenance 200-300 mg tid-qid or  300-600 mg q8-12hr</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1032">
						<sec_title>Hiccups (unlabeled)</sec_title>
						<section type="none" id="sidelem4x1040">
							<label>•</label>
							<sec_title>Adult<route> PO</route></sec_title>
							<para>
								<list id="lidelem4x1040">
									<item>
										<label>•</label>
										<para> 200 mg qid</para>
									</item>
								</list>
							</para>
						</section>
					</section>
					<section type="none" id="sidelem4x1044">
						<sec_title>Available forms:</sec_title>
						<para> <emphasis style="italic">Gluconate:</emphasis> ext rel tabs 324 mg; inj gluconate 80 mg/ml; <emphasis style="italic">sulfate:</emphasis> tabs 200, 300 mg; sus rel tabs 300 mg</para>
					</section>
					<section type="none" id="sidelem4x1055">
						<sec_title>Administer:</sec_title>
						<para>
							<list id="lidelem4x1059">
								<item>
									<label>•</label>
									<para>AV node blocker (digoxin) before starting quinidine to avoid increased ventricular rate</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1066">
							<sec_title>PO route</sec_title>
							<para>
								<list id="lidelem4x1071">
									<item>
										<label>•</label>
										<para>Do not break, crush, chew ext rel products</para>
									</item>
								</list>
							</para>
							<para>
								<list id="lidelem4x1076">
									<item>
										<label>•</label>
										<para>With full glass of water on empty stomach; if GI upset occurs, may take with food</para>
									</item>
								</list>
							</para>
							<section type="none" id="sidelem4x1084">
								<label>•</label>
								<sec_title>
									<route>Sus rel forms not interchangeable</route>
								</sec_title>
							</section>
							<para>
								<list id="lidelem4x1087">
									<item>
										<label>•</label>
										<para>Do not use with grapefruit juice</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1092">
							<sec_title>IM route</sec_title>
							<para>
								<list id="lidelem4x1096">
									<item>
										<label>•</label>
										<para>IM inj in deltoid; aspirate to avoid intravascular administration</para>
									</item>
								</list>
							</para>
						</section>
						<section type="none" id="sidelem4x1102">
							<sec_title>Intermittent IV INFUSION route</sec_title>
							<para>
								<list id="lidelem4x1106">
									<item>
										<label>•</label>
										<para>After diluting 800 mg/50 ml D<emphasis style="inf">5</emphasis>W (16 mg/ml); give ≤1 mg/min, use infusion pump; quiNIDine absorbed by PVC tubing, minimize length</para>
									</item>
								</list>
							</para>
							<para>
								<emphasis style="bold">Y-site compatibilities:</emphasis> Alfentanil, amikacin, anidulafungin, argatroban, arsenic trioxide, ascorbic acid, asparaginase, atenolol, atracurium, atropine, benztropine, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, caspofungin, chlorproMAZINE, cimetidine, CISplatin, cyanocobalamin, cycloSPORINE, DACTINomycin, digoxin, diltiazem, diphenhydrAMINE, DOBUTamine, DOCEtaxel, DOPamine, doxycycline, enalaprilat, ePHEDrine, EPINEPHrine, epoetin alfa, erythromycin, esmolol, etoposide, famotidine, fenoldopam, fentaNYL, fluconazole, fludarabine, gatifloxacin, gemcitabine, gentamicin, glycopyrrolate, granisetron, HYDROmorphone, IDArubicin, imipenem-cilastatin, irinotecan, isoproterenol, labetalol, lidocaine, linezolid, LORazepam, magnesium sulfate, mannitol, mechlorethamine, meperidine, metaraminol, methoxamine, methyldopate, metoclopramide, metoprolol, metroNIDAZOLE, miconazole, milrinone, mitoXANtrone, morphine, multiple vitamins, mycophenolate, nalbuphine, naloxone, nesiritide, netilmicin, nitroglycerin, norepinephrine, octreotide, ondansetron, oxaliplatin, PACLitaxel, palonosetron, pamidronate, pancuronium, papaverine, pentamidine, pentazocine, phenylephrine, phytonadione, polymyxin B, potassium chloride, procainamide, prochlorperazine, promethazine, propranolol, protamine, pyridoxine, ranitidine, ritodrine, succinylcholine, SUFentanil, tacrolimus, teniposide, theophylline, thiamine, thiotepa, tirofiban, tobramycin, tolazoline, trimetaphan, urokinase, vancomycin, vasopressin, verapamil, vinorelbine, voriconazole, zoledronic acid</para>
						</section>
					</section>
				</section>
			</section>
			<section type="effects" id="sidelem4x1119">
				<sec_title>Side effects</sec_title>
				<section type="none" id="sidelem4x1122">
					<section type="none" id="sidelem4x1123">
						<sec_title>CNS:</sec_title>
						<para> <emphasis style="italic">Headache, dizziness,</emphasis> involuntary movement, confusion, psychosis, restlessness, irritability, syncope, excitement, depression, ataxia</para>
					</section>
					<section type="none" id="sidelem4x1131">
						<sec_title>CV:</sec_title>
						<para> <emphasis style="bold">Hypotension,</emphasis><emphasis style="italic">bradycardia,</emphasis> PVCs, <emphasis style="bold">heart block, CV collapse, arrest,</emphasis> torsades de pointes, widening QRS complex, <emphasis style="bold">ventricular tachycardia</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1146">
						<sec_title>EENT:</sec_title>
						<para> Cinchonism: tinnitus, blurred vision, hearing loss, mydriasis, disturbed color vision</para>
					</section>
					<section type="none" id="sidelem4x1151">
						<sec_title>GI:</sec_title>
						<para> Nausea, vomiting, anorexia, abdominal pain, <emphasis style="italic">diarrhea,</emphasis><emphasis style="bold">hepatotoxicity</emphasis></para>
					</section>
					<section type="none" id="sidelem4x1160">
						<sec_title>HEMA:</sec_title>
						<para> <emphasis style="bold">Thrombocytopenia,</emphasis> hemolytic anemia, <emphasis style="bold">agranulocytosis,</emphasis> hypoprothrombinemia</para>
					</section>
					<section type="none" id="sidelem4x1171">
						<sec_title>INTEG:</sec_title>
						<para> Rash, urticaria, <emphasis style="bold">angioedema,</emphasis> swelling, photosensitivity, flushing with severe pruritus</para>
					</section>
					<section type="none" id="sidelem4x1179">
						<sec_title>RESP:</sec_title>
						<para> Dyspnea, <emphasis style="bold">respiratory depression</emphasis></para>
					</section>
				</section>
			</section>
			<section type="kinetics" id="sidelem4x1186">
				<sec_title>Pharmacokinetics</sec_title>
				<section type="none" id="sidelem4x1189">
					<section type="none" id="sidelem4x1190">
						<sec_title>PO:</sec_title>
						<para> (sulfate) peak 1-6 hr, duration 6-8 hr, (Sulfate ER) peak 4 hr, duration 8-12 hr; (gluconate PO) peak 3-4 hr, duration 6-8 hr, half-life 6-7 hr (prolonged in geriatric patients, cirrhosis, CHF), metabolized in liver, excreted unchanged (10%-50%) by kidneys, protein bound (80%-90%)</para>
					</section>
				</section>
			</section>
			<section type="interactions" id="sidelem4x1195">
				<sec_title>Interactions</sec_title>
				<para>
					<list id="lidelem4x1199">
						<item>
							<label>•</label>
							<para>Additive vagolytic effect: anticholinergic blockers</para>
						</item>
					</list>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> cardiac depression: other antidysrhythmics, phenothiazines, reserpine</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> effects of neuromuscular blockers, digoxin, warfarin, tricyclics, propranolol</para>
				<para>
					<emphasis alert="lifethreat">Increase: QT prolongation—macrolides, quinolones, tricyclics procainamide, antipsychotics</emphasis>
				</para>
				<para>
					<emphasis style="bold">Increase:</emphasis> quiNIDine effects—cimetidine, sodium bicarbonate, carbonic anhydrase inhibitors, antacids, hydroxide suspensions, amiodarone, verapamil, NIFEdipine, protease inhibitors</para>
				<para>
					<emphasis style="bold">Decrease:</emphasis> quiNIDine effects—barbiturates, phenytoin, rifampin, sucralfate, cholinergics</para>
				<section type="none" id="sidelem4x1226">
					<section type="none" id="sidelem4x1227">
						<sec_title>Drug/Herb</sec_title>
						<para>
							<emphasis style="bold">Increase:</emphasis> quiNIDine effect—hawthorn, licorice</para>
					</section>
					<section type="none" id="sidelem4x1234">
						<sec_title>Drug/Food</sec_title>
						<para>
							<list id="lidelem4x1238">
								<item>
									<label>•</label>
									<para>Delayed absorption, decreased metabolism: grapefruit juice</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1244">
						<sec_title>Drug/Lab Test</sec_title>
						<para>
							<emphasis style="bold">Decrease:</emphasis> platelets, Hgb, granulocytes</para>
					</section>
				</section>
			</section>
			<section type="considerations" id="sidelem4x1251">
				<sec_title>Nursing considerations</sec_title>
				<section type="none" id="sidelem4x1254">
					<section type="none" id="sidelem4x1255">
						<sec_title>Assess:</sec_title>
						<para>
							<list id="lidelem4x1261">
								<item>
									<para>
										<emphasis alert="nurse">ECG B/P, pulse continuously during IV, baseline, and periodically (PO) to determine increased PR or QRS segments, QT interval; discontinue product or reduce dose</emphasis>
									</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1266">
								<item>
									<label>•</label>
									<para>Blood levels (therapeutic level 2-7 mcg/ml), CBC, LFTs</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1272">
								<item>
									<para>
										<emphasis alert="nurse">For cinchonism: tinnitus, headache, nausea, dizziness, fever, vertigo, tremors; may lead to hearing loss</emphasis>
									</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1280">
							<label>•</label>
							<sec_title>Cardiac toxicity<route> asystole, ventricular dysrhythmias, widening QRS, torsades de pointes</route></sec_title>
						</section>
						<para>
							<list id="lidelem4x1283">
								<item>
									<label>•</label>
									<para>CNS effects: dizziness, confusion, psychosis, paresthesias, seizures; product should be discontinued</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1291">
							<label>•</label>
							<sec_title>Hepatotoxicity<route> monitor LFTs for first 1-2 mo of treatment</route></sec_title>
						</section>
					</section>
					<section type="none" id="sidelem4x1294">
						<sec_title>Evaluate:</sec_title>
						<para>
							<list id="lidelem4x1298">
								<item>
									<label>•</label>
									<para>Therapeutic response: decreased dysrhythmias</para>
								</item>
							</list>
						</para>
					</section>
					<section type="none" id="sidelem4x1304">
						<sec_title>Teach patient/family:</sec_title>
						<para>
							<list id="lidelem4x1309">
								<item>
									<label>•</label>
									<para>That if dizziness, drowsiness occurs, to avoid driving or hazardous activities</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1314">
								<item>
									<label>•</label>
									<para>To use sunglasses; product may cause sensitivity to light</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1319">
								<item>
									<label>•</label>
									<para>To carry emergency ID stating disease, medication use</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1324">
								<item>
									<label>•</label>
									<para>How to take pulse; when to notify prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1329">
								<item>
									<label>•</label>
									<para>To avoid all products unless approved by prescriber</para>
								</item>
							</list>
						</para>
						<para>
							<list id="lidelem4x1334">
								<item>
									<label>•</label>
									<para>Not to crush, chew ext rel product</para>
								</item>
							</list>
						</para>
						<section type="none" id="sidelem4x1343">
							<label>•</label>
							<sec_title>
								<route>Not to use grapefruit juice with this product</route>
							</sec_title>
						</section>
						<section type="none" id="sidelem4x1349">
							<label>•</label>
							<sec_title>QuiNIDine toxicity<route> visual changes, nausea, headache, ringing in the ears; report immediately</route></sec_title>
						</section>
						<section type="none" id="sidelem4x1355">
							<label>•</label>
							<sec_title>
								<route>To report signs of cinchonism, diarrhea, anorexia, decreased B/P</route>
							</sec_title>
						</section>
					</section>
				</section>
			</section>
		</monograph>
</alpha>
</drug_guide>